Jim Simons Milestone Pharmaceuticals Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.85 - $4.4 $48,353 - $74,650	16,966 Added 18.48%	108,766 $310,000
Q1 2023 May 12, 2023	BUY	$3.14 - $4.2 $77,244 - $103,320	24,600 Added 36.61%	91,800 $362,000
Q4 2022 Feb 13, 2023	BUY	$3.53 - $9.5 $237,216 - $638,400	67,200 New	67,200 $266,000
Q4 2021 Feb 11, 2022	SELL	$5.47 - $7.13 $144,408 - $188,232	-26,400 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.28 - $6.29 $428,493 - $510,458	-81,154 Reduced 75.45%	26,400 $151,000
Q2 2021 Aug 13, 2021	SELL	$5.22 - $6.11 $568,176 - $665,049	-108,846 Reduced 50.3%	107,554 $592,000
Q1 2021 May 13, 2021	BUY	$5.79 - $8.85 $303,396 - $463,740	52,400 Added 31.95%	216,400 $1.25 Million
Q4 2020 Feb 10, 2021	BUY	$5.57 - $7.66 $829,373 - $1.14 Million	148,900 Added 986.09%	164,000 $1.1 Million
Q3 2020 Nov 13, 2020	BUY	$3.34 - $9.8 $50,434 - $147,980	15,100 New	15,100 $111,000
Q2 2020 Aug 13, 2020	SELL	$1.77 - $4.56 $18,128 - $46,703	-10,242 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$1.7 - $22.5 $17,411 - $230,445	10,242 New	10,242 $19,000

28.7M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $54M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.